Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

parathyroid hormone

- PMLiVE

Novartis bags EU approvals for three ex-GSK drugs

Revolade, Tafinlar and Mekinist all receive regulatory approval

- PMLiVE

Industry files complaint against France’s off-label law

Protests against promotion of Roche's Avastin as cheap eye medication

- PMLiVE

J&J files three-monthly schizophrenia drug in Europe

Hopes to gain advantage over its competitors

- PMLiVE

AZ and Peregrine join forces on cancer trial

Another oncology deal for the company after a recent spate of deals

- PMLiVE

Novartis buys rights to GSK’s Arzerra in MS for $1bn

Comes after a recent ‘asset swap’ between the firms worth $20bn 

Celgene building

Myeloma market set to be $9bn by 2021

New research shows it will pushed by a growing prevalence of the disease

- PMLiVE

EU green light for Novartis’ skin cancer therapy

Swiss firm’s basal cell carcinoma treatment can now be launched across Europe

- PMLiVE

Novartis licenses cancer support drug from Aveo Oncology

Swiss firm buys into drug to alleviate a wasting syndrome that is seen in chronic patients

- PMLiVE

Healthcare gets more independence in Google restructuring

New ‘Alphabet’ company will put tech giant’s health ventures centre-stage

Shire Basingstoke

Baxalta spells out opposition to Shire

Firm has rejected unsolicited $30bn bid from the Irish biopharma

- PMLiVE

Shire makes shock $30bn bid for Baxalta

Irish firm seeking to buy the newly spun-out biotech that used to be part of Baxter

Shire Basingstoke

Shire buys into eyecare specialist

Will complement its investigational dry eye drug lifitegrast

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links